This page is translated by Google and can contain errors. Go back to English.

News

Breast cancer: initial trial results suggest new treatment combination for some patients

A Cambridge-led trial testing a potential new treatment combination for post-menopausal women with hormone driven breast cancer reports positive findings at the international San Antonio Breast Cancer Symposium.

The results show that either a high or low dose of megestrol when given with the standard hormone therapy, letrozole, could be more effective in stopping tumour growth than letrozole alone.

During Pancreatic Cancer Awareness Month, the Anticancer Fund redoubles its efforts

The Anticancer Fund aims to intensify its commitment to helping patients confronted with pancreatic cancer and finding solutions for treatment. As November marks Pancreatic Cancer Awareness Month, we underscore the urgent need for dedicated research during a meeting of the European REMEDi4ALL consortium.

CTOS 2023: dedicated to improving outcomes for sarcoma patients

The Anticancer Fund, a non-profit organisation dedicated to advancing cancer research and treatment, is proud to announce its active participation in the annual Connective Tissue Oncology Society (CTOS) meeting, taking place in Dublin, Ireland. Two of the clinical trials we support, will present their findings at the conference.

Empowering older adults with cancer: webinar on Shared decision-making

The Anticancer Fund (ACF) and the International Society of Geriatric Oncology (SIOG) are collaborating to present an interactive webinar focused on enhancing cancer care for older adults: Shared decision-making in Geriatric Oncology.

Young man with cancer inspires with resilience and generosity: Gilles Van der Spek’s remarkable fundraising efforts

In the face of adversity, Gilles van der Spek, a 35-year old diagnosed with incurable cancer, has shown resilience and determination. He started raising funds for the Anticancer Fund and in doing so, embarked on a journey that captured hearts globally.

First patients for trial that investigates adaptive treatment for ovarian cancer

The Anticancer Fund and Barts Charity are co-funding the ACTOv-trial, which has enrolled its first patients in the United Kingdom. This study is investigating a new personalised treatment approach for ovarian cancer that has returned after previous chemotherapy. The aim is to prolong patients’ survival and reduce side-effects.